Jump to main content
Jump to site search


Glutathione Triggering Degradation of Polydopamine to Facilitate Controlled Drug Release for Synergic Combinational Cancer Treatment

Abstract

Here we report a novel mechanism for triggering drug release in the polydopamine (PDA)-coated magnetic CuCo2S4 core-shell nanostructure by glutathione (GSH) triggering degradation of PDA for releasing. In the design, PDA coated CuCo2S4 as the nanocarriers with polyethylene glycol and folic acids targeting molecules to ensure the safe delivery of doxorubicin (DOX) to the cancer cells. In addition, the controlled release can be enforced by taking the advantage of PDA pH sensitivity to the tumor acidic environments. The targeting and treatment on HeLa cancer cells were very effective and the killing is more efficient at higher levels of GSH. Furthermore, the system designed not only can be used for drug delivery but also can combine photothermal therapy with chemotherapy in a synergetic way. Plus, the system can be used for magnetic resonance imaging, which is beneficial for imaging-guided treatment.

Back to tab navigation

Supplementary files

Publication details

The article was received on 08 Jul 2019, accepted on 12 Aug 2019 and first published on 14 Aug 2019


Article type: Paper
DOI: 10.1039/C9TB01400D
J. Mater. Chem. B, 2019, Accepted Manuscript

  •   Request permissions

    Glutathione Triggering Degradation of Polydopamine to Facilitate Controlled Drug Release for Synergic Combinational Cancer Treatment

    Y. Hao, A. Zheng, T. Guo, Y. Shu, J. Wang, O. Johnson and W. Chen, J. Mater. Chem. B, 2019, Accepted Manuscript , DOI: 10.1039/C9TB01400D

Search articles by author

Spotlight

Advertisements